(RTTNews) - Ionis Pharmaceuticals Inc. (IONS) announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBVRx), an ...

SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted ...

Hepatitis B viral load is the amount of hepatitis B virus (HBV) found in a person’s bloodstream. Hepatitis B is a viral infection that can pass from person to person through bodily fluids. It ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 ...

Three scenarios can occur after spontaneous seroconversion from HBeAg to anti-HBe: Most individuals go into the inactive hepatitis B phase ("inactive carrier"), characterized by normalization of serum ...

An ad hoc committee under the auspices of the Institute of Medicine will be convened to complete a two phase study on hepatitis B and C elimination. The IOM will conduct a literature review and ...

As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that policymakers set clear elimination targets for hepatitis B, coordinate efforts, ...

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...

– Initial SOLSTICE data suggests the potential of VIR-3434 + VIR-2218 to address the unmet need for a highly efficacious hepatitis delta therapy – – New MARCH Part B data demonstrate that VIR-3434 may ...